Skip to content

Tarsus Pharmaceuticals

US · TARS #2389 by market cap Listed 2020
73.01 -4.66 -6.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
B
Momentum strategy signal
Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Mixed
1
■ Upgrades■ Downgrades
  • 1 upgrade vs 0 downgrades among tracked analyst rating changes.
  • Most recent: Goldman Sachs moved from Hold to Buy on 2026-09-24.

Analyst consensus 8 analysts

Buy
Avg price target 105.57 +44.6%
Price target rangecurrent 73.01
Low97.00
Avg105.57
High116.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-11 Barclays -- Buy 110.00
2026-11-06 Mizuho Securities -- Buy 102.00
2026-11-04 BofA Securities -- Buy --
2026-11-04 Guggenheim -- Buy 97.00
2026-11-04 H.C. Wainwright -- Buy 106.00
2026-11-04 Oppenheimer -- Buy 103.00
2026-10-29 Mizuho Securities -- Buy 94.00
2026-10-12 BofA Securities -- Buy 84.00
2026-10-09 Barclays -- Buy 110.00
2026-10-02 Oppenheimer -- Buy 100.00
2026-09-24 Goldman Sachs -- Buy 116.00
2026-09-16 Barclays -- Buy 110.00
2026-09-08 Jefferies -- Buy 105.00
2026-08-12 William Blair -- Buy --
2026-08-12 Oppenheimer -- Buy 100.00
2026-08-11 Mizuho Securities -- Buy 100.00
2026-08-08 LifeSci Capital -- Buy 104.00
2026-08-07 LifeSci Capital -- Buy 104.00
2026-08-07 Mizuho Securities -- Buy 100.00
2026-08-07 H.C. Wainwright -- Buy 88.00
2026-08-04 Mizuho Securities -- Buy 98.00
2026-07-31 Mizuho Securities -- Buy 98.00
2026-07-21 Guggenheim -- Buy 89.00
2026-07-21 Oppenheimer -- Buy 97.00
2026-07-14 William Blair -- Buy --

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-09-24 Goldman Sachs Hold → Buy 116.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-03 -- ±13.75% -0.93% (in line)
2026/Q2 2026-08-06 -- ±11.25% +6.59% (in line)
2026/Q1 2026-05-06 After close ±13.47% -1.24% (in line)
2025/Q4 2026-02-23 After close ±14.71% +7.79% (in line)
2025/Q3 2025-11-04 After close ±12.86% -4.62% (in line)
2025/Q2 2025-08-06 After close ±17.32% +15.15% (in line)
2025/Q1 2025-05-01 After close ±14.67% -5.84% (in line)
2024/Q4 2025-02-25 -- ±16.97% -9.33% (in line)
2024/Q3 2024-11-13 After close ±23.27% +0.31% (in line)
2024/Q2 2024-08-08 After close ±16.52% +13.72% (in line)
2024/Q1 2024-05-08 After close ±18.63% -8.86% (in line)
2023/Q4 2024-02-27 -- ±14.92% -3.44% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

Tarsus Pharmaceuticals discussion 0 comments

Add a comment